Advanced Technology Boosting Immunotherapy
eTheRNA is managed by an experienced team of committed biotech professionals.
A team dedicated to bringing eTheRNA’s mRNA-based TriMix technology to the next level.
Since its inception, eTheRNA has raised a total amount of over EUR 58 million in equity investment, including a Series A financing of EUR 24 million announced in 2016 and Series B financing of EUR 34 million announced mid-2020.
© 2021 eTheRNA | Studio Hanswijk